Lupin Collaborated with Enzene Biosciences to Launch Cetuximab in India

Share this

Lupin Collaborated with Enzene Biosciences to Launch Cetuximab in India


  • The companies collaborated to launch Cetuximab, the first biosimilar developed for Cetuximab in India to treat patients with head & neck cancer. Cetuximab is available as a 100mg vial
  • The DCGI has approved cetuximab due to its efficacy in treating head and neck cancer incl. SCCHN. In 2009, Eli Lily and Merck’s Erbitux (cetuximab) have been approved by the US FDA for metastatic colorectal cancer and head and neck cancer
  • Lupin develops & commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in ~100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), EU, and Middle East regions

Ref: Lupin | Image: Lupin

Related News:- Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) for KRASG12C-Mutated NSCLC in China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions